Wen, P., Aguilar, L., Ye, X., Reardon, D., Bi, W. L., Peruzzi, P., Patel, N., Strowd, R., Tatter, S., Lee, I., Walbert, T., Snyder, J., Brem, S., Desai, A., Bagley, S., Amankulor, N., Lieberman, F., Mantica, M., Lopez, L., Bell, S., Manzanera, A., Barone, F., Guzik, B., Lawler, S., Jin, L., Timmer, W., Danda, N., Desideri, S., Nabors, L. B., Grossman, S., Aguilar-Cordova, E., Tak, P. P., & Chiocca, E. A. (2021). cTIM-13. PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG). Neuro-oncology, 23, vi52. http://access.bl.uk/ark:/81055/vdc_100146090179.0x00002b